Navigation Links
Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative
Date:9/11/2019

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D in the areas of oncology, the central nervous system, and other medical indications.

“As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes,” said Tim Holmström, Head of Biologics at Orion Pharma. “Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization. Also, collaborating with CROs is a key part of our strategy, so we require an open and scalable system able to capture and integrate all data generated by our CRO network. Finally, Genedata’s offering of Software-as-a-Service (SaaS) was an additional plus because we wanted a self-maintaining model that provides regular upgrades of new, innovative functionalities.”

Genedata Biologics enables Orion scientists to easily capture, process, and interpret all large-molecule R&D data and facilitate the design of antibodies. Further, it integrates all assay and analytics data to enable a comprehensive assessment of all drug candidates. The platform helps eliminate error-prone manual processes by providing a robust, standardized data repository that can be integrated with laboratory instrumentation. All molecule, sample, assay and analytics data, including developability and manufacturability data, are managed within one fully integrated system and are shared between different project teams and sites. The platform facilitates systematic and transparent decision-making to select drug candidates to be progressed through the development pipeline.

“We are very pleased that Orion, an innovative R&D-based pharmaceutical company, has selected Genedata Biologics as their workhorse platform for their biopharma R&D operations. By providing Orion with a backbone that covers their entire discovery pipeline in a single system, we help to increase the efficiency of their R&D processes and speed up decision making,” said Dr. Othmar Pfannes, CEO of Genedata. “Our technology, combined with Orion’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

http://www.genedata.com

Follow Us on LinkedIn.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at https://www.prweb.com/releases/orion_pharmaceuticals_implements_genedata_biologics_to_support_new_large_molecule_r_d_initiative/prweb16561443.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
2. eHealth Technologies and Orion Health Announce Partnership
3. Tobira Therapeutics Announces Initiation of ORION, a Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease
4. Saint Francis Healthcare Partners Selects Orion Healths Precision Medicine Platform
5. HealthInfoNet Selects Orion Healths Precision Medicine Platform
6. Orion Health Begins Migration of Patient Records to Amazon Web Services
7. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
8. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. Access Pharmaceuticals Reports First Quarter Results
11. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... , ... October 08, 2019 , ... Dr. Ryan McNally, ... the 2019 Academy of Integrative Health and Medicine conference. Their presentation titled Advances in ... treatments and how they can be used to promote brain health, and reduce the ...
(Date:10/8/2019)... ... October 08, 2019 , ... For many Americans, dental insurance is limited ... paid out of pocket. Yearly insurance payouts are generally capped at around $1,500—which doesn’t ... million people who are 65 or older. (Standard Medicare does not cover any dental ...
(Date:10/8/2019)... ... October 08, 2019 , ... DuPont today announced a new ... Design Expo (HCD) from Nov. 3-5, 2019, in New Orleans. , DuPont™ Tedlar® ... Since its installation in the early 1980s in the Omega Medical Center, the ...
Breaking Medicine Technology:
(Date:10/17/2019)... ... 2019 , ... A clinical article reviewing the long-term performance of the latest ... Plastic Surgery - The Meeting 2019 in San Diego last month. The article, titled ... Larry S. Nichter, M.D., Robert A. Hardesty, M.D., and Gregg M. Anigian, M.D., and ...
(Date:10/15/2019)... ... ... An October 3 article on CNN Health explains why people should ... both agents are mildly abrasive; so while they may be good at removing surface ... also good at stripping the enamel off of teeth if used often. This can ...
(Date:10/15/2019)... ... October 15, 2019 , ... Genomenon® announced today at the ... that includes incorporating the Mastermind® Genomic Search Engine into the SOPHiA ... research at the fingertips of clinical researchers performing genomic analysis worldwide. , ...
(Date:10/11/2019)... Calif. (PRWEB) , ... October 11, 2019 , ... Inland ... of Temecula, CA. The new location has incredible views of the Temecula Valley and ... On 2.5 acres, the new facility offers both private rooms as well as double ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... ... management consulting and information technology (IT) services for the healthcare industry, has completed ... Public Hospitals Authority (PHA) of the Commonwealth of The Bahamas towards a fully ...
Breaking Medicine News(10 mins):